MRC-Holland b.v. is a biotechnology company located in Amsterdam, the Netherlands.
The company is a follow-up of Microbiology Research Centre Holland, founded in 1985 by dr. Jan Schouten. Until 2000, the main products of MRC-Holland were restriction endonucleases -purified from a wide range of bacteria and blue green algae- and DNA molecular weight markers.
These products were sold in bulk amounts to distributing companies worldwide.
In 1997, MRC-Holland started focusing on developing new techniques for DNA analysis.
By far the most successful technique developed is Multiplex Ligation-dependent Probe Amplification, or MLPA®.
The MLPA® technology was first described in Nucleic Acid Research 30, e57 (2002) by Schouten et al.
Since then, hundreds of MLPA probe sets have been developed for a wide variety of genes and applications, some of which very rare.
At present, all activities of MRC-Holland are directed to the production of new MLPA-based products and the development of novel MLPA-based techniques, such as the MS-MLPA technique for DNA methylation testing. MRC-Holland currently has about 35 employees, working in development, quality testing, production, sales and customer service.
MLPA® is a rapid, high-throughput technique for copy number quantification. Applications include:
Congenital & Hereditary Disorders
Tumours Profiling
Methylation profiling
Quantification of mRNA
|
